<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539656</url>
  </required_header>
  <id_info>
    <org_study_id>J0606</org_study_id>
    <secondary_id>NA_00001903</secondary_id>
    <secondary_id>M052663</secondary_id>
    <nct_id>NCT00539656</nct_id>
  </id_info>
  <brief_title>Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers</brief_title>
  <acronym>Cord Blood</acronym>
  <official_title>Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety of transplantation of two cord blood products, including&#xD;
      toxicities in patients following high-dose, myeloablative chemotherapy for blood&#xD;
      malignancies. It is also to determine if the use of two cord products results in an&#xD;
      improvement in neutrophil engraftment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The success of BMT as a curative option for patients with malignancies is frequently limited&#xD;
      by the inability to identify an appropriate donor in time for transplantation.&#xD;
&#xD;
      Transplantations utilizing umbilical cord blood stem cells are increasingly successful. Data&#xD;
      suggest that there are fewer and less developed T-cells in cord products when compared to&#xD;
      bone marrow and so are likely to produce less graft-vs.-host disease (GVHD) even in the&#xD;
      mismatched setting. In addition, the grafts are easily available second to the ease of&#xD;
      collection as compared with other sources such as bone marrow and peripheral blood stem cells&#xD;
      (PBSCs). The ability to build cord blood repositories containing samples with HLA types from&#xD;
      minorities has and will continue to increase the likelihood of finding suitable products for&#xD;
      under represented minorities such as African-Americans, Hispanic populations and mixed ethnic&#xD;
      populations.&#xD;
&#xD;
      Unfortunately, limitations remain, secondary to the time to engraftment when the cell dose is&#xD;
      less than optimal, resulting in delayed or failed engraftment. In addition, increased cell&#xD;
      dose appears to be associated with disease free survival. Therefore, this modality of&#xD;
      transplant is generally limited to smaller patients. This protocol evaluates the infusion and&#xD;
      engraftment of two cord blood products - one that has been expanded ex vivo and one that has&#xD;
      not been expanded following myeloablative chemotherapy for the treatment of hematological&#xD;
      malignancies.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      -To evaluate the safety of transplantation of two cord products including an expanded unit&#xD;
      including infusional toxicities and potential immunologic competition.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      -To determine if the use of two cord products results in an improvement in neutrophil&#xD;
      engraftment (ANC&gt;500) in subjects as demonstrated by engraftment &lt;=21 days.&#xD;
&#xD;
      Tertiary Objectives:&#xD;
&#xD;
      Patients will be compared with patients participating in other trials at our institution and&#xD;
      to those who receive therapy as per standard of care.&#xD;
&#xD;
        -  To evaluate the rate, extent, and durability of hematopoietic reconstitution and in&#xD;
           particular to determine the relative contribution of each cord unit in early engraftment&#xD;
           and long-term engraftment&#xD;
&#xD;
        -  To estimate the rate and severity of graft-vs-host disease&#xD;
&#xD;
        -  To estimate the rates of infectious complications&#xD;
&#xD;
        -  To obtain preliminary data regarding disease-free and overall survival&#xD;
&#xD;
        -  To collect samples for future studies of immune reconstitution and for future studies in&#xD;
           the laboratory regarding disease and the immune system&#xD;
&#xD;
      We will be able to track the fate of both the unmanipulated and expanded CB progenitors by&#xD;
      evaluating differences in the cord products and the recipient by evaluation of sex mismatch,&#xD;
      HLA type and/or restriction length polymorphisms (RFLPs). If the expanded CB cells are&#xD;
      detected in the patients long-term, this will give us confidence to use expanded CB as the&#xD;
      sole hematopoietic progenitor cell support, in future studies.&#xD;
&#xD;
      The major risk is non-engraftment of either one or both of the cord blood units.&#xD;
      Non-engraftment of one of the units may lead to prolonged cytopenia and a marked increased&#xD;
      risk for infection. Failure of either unit to engraft as defined as failure to detect cells&#xD;
      from either cord blood product at Day +60 is likely to result in the death of the subject.&#xD;
      There is the possibility of failure of long-term engraftment from both cords. This would be&#xD;
      fatal unless an alternative donor option was identified or the unlikely event of autologous&#xD;
      reconstitution of bone marrow. There is a possibility of an immune competition of both cord&#xD;
      blood products . This could result in the loss of the cord product that would have been&#xD;
      responsible for long term engraftment. There is a possibility of the expanded cord product to&#xD;
      fail release testing. In this event, only the unexpanded cord would be infused and would&#xD;
      likely result in delayed engraftment.&#xD;
&#xD;
      As with all cellular products there are risks associated with the infusion including but not&#xD;
      limited to anaphylaxis, transfusion reaction, hemolysis, side-effects of the DMSO that the&#xD;
      product is stored in (bradycardia, hypothermia, neurologic changes). The expanded product&#xD;
      will be washed however there remains a small chance that a small amount of growth factor&#xD;
      remains. The risk associated with these will be allergic.&#xD;
&#xD;
      Busulfan toxicity&#xD;
&#xD;
        1. Nausea and vomiting&#xD;
&#xD;
        2. Myeloablation&#xD;
&#xD;
        3. Pulmonary complications&#xD;
&#xD;
        4. Seizures&#xD;
&#xD;
        5. Other toxic effects which may be produced by Busulfan erythematous skin rash,&#xD;
           hyperpigmentation, hepatic dysfunction, amenorrhea, testicular atrophy, gynecomastia,&#xD;
           myasthenia symptoms, cataract and atrophic bronchitis associated with cytologic&#xD;
           dysplasia.&#xD;
&#xD;
      Cyclophosphamide Toxicity&#xD;
&#xD;
        1. Leukopenia, anemia&#xD;
&#xD;
        2. Alopecia&#xD;
&#xD;
        3. Nausea, vomiting, increased AST, ALT, mucositis, diarrhea&#xD;
&#xD;
        4. Headache, dizziness&#xD;
&#xD;
        5. Cardiac necrosis rarely with high dose cyclophosphamide&#xD;
&#xD;
        6. Hemorrhagic cystitis, SIADH&#xD;
&#xD;
        7. Teratogenic, may cause secondary neoplasms, anaphylaxis (rare)&#xD;
&#xD;
        8. Fluid retention.&#xD;
&#xD;
        9. Cardiomyopathy.&#xD;
&#xD;
       10. Hemorrhagic Cystitis.&#xD;
&#xD;
      At the doses used for uroprotection mesna is virtually non-toxic. However, adverse effects&#xD;
      which may be attributable to mesna include nausea and vomiting, diarrhea, abdominal pain,&#xD;
      altered taste, rash, urticaria, headache, joint or limb pain, hypotension and fatigue.&#xD;
&#xD;
      Total Body Irradiation Toxicity:&#xD;
&#xD;
        1. Nausea and Vomiting&#xD;
&#xD;
        2. Alopecia&#xD;
&#xD;
        3. Parotitis and Pancreatitis&#xD;
&#xD;
        4. Diarrhea&#xD;
&#xD;
        5. Fever&#xD;
&#xD;
        6. Erythema&#xD;
&#xD;
        7. Hyperpigmentation&#xD;
&#xD;
        8. Mucositis&#xD;
&#xD;
        9. Late Effects - cataract formation, growth retardation, carcinogenesis and the&#xD;
           probability of sterilization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The manufacturer discontinued necessary reagents.&#xD;
  </why_stopped>
  <start_date type="Actual">December 20, 2007</start_date>
  <completion_date type="Actual">October 20, 2009</completion_date>
  <primary_completion_date type="Actual">October 20, 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Toxicities Related to Infusion of Expanded Cord Blood Products</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophil Engraftment Within 21 Days</measure>
    <time_frame>21 days</time_frame>
    <description>Number of participants who reached 3 consecutive days with ANC &gt; 500</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>100 days</time_frame>
    <description>Number of participants who died without relapse in less than 100 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Leukemia, Lymphoblastic, Acute</condition>
  <condition>Leukemia, Bilineage, Acute</condition>
  <condition>Leukemia, Myeloid, Chronic</condition>
  <arm_group>
    <arm_group_label>Receive two cord blood units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One cord blood unit will be thawed on day -14 before transplantation and selected using the CliniMACS for primitive cells that express CD133. These cells will be expanded ex vivo for a total of 14 days, using a two-stage procedure. On Day 0 the expanded cells will be harvested, washed three times with CliniMACS buffer (Miltenyi) plus 1% HSA per standard laboratory and clinical practice and the expanded cell product will be infused to a patient who has been prepared with a standard, myeloablative preparative regimen. A second, unexpanded, cord blood product will be infused on Day +1 for safety.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ex vivo expansion of cord blood</intervention_name>
    <description>Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused</description>
    <arm_group_label>Receive two cord blood units</arm_group_label>
    <other_name>Miltenyi CliniMACS CD133</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have two cord units available. Units must be minimally matched to the&#xD;
             subject at 4/6 antigens (HLA Class I (A or B) and Class II (DRB1) - units must have at&#xD;
             lease one HLA DRB1 matched allele) and at least one unit must contain a minimum of 1.0&#xD;
             x 107 Total Nucleated Cells /Kg but neither unit may have &gt; 5 x 107Total Nucleated&#xD;
             Cells /Kg. (The feasibility of using particular units will be discussed with the&#xD;
             Principal Investigators)&#xD;
&#xD;
          -  Disease status precludes waiting to identify a suitably HLA matched unrelated donor&#xD;
&#xD;
          -  Patients must have a diagnosis of one of the following:&#xD;
&#xD;
               -  AML&#xD;
&#xD;
               -  refractory AML&#xD;
&#xD;
               -  Secondary AML&#xD;
&#xD;
               -  ALL in CR2 with high-risk features such as short CR1 and/or high-risk&#xD;
                  cytogenetics&#xD;
&#xD;
               -  ALL in CR1 following initial induction failure&#xD;
&#xD;
               -  Acute mixed lineage leukemia&#xD;
&#xD;
               -  CML beyond chronic phase 1.&#xD;
&#xD;
               -  Lymphoma (Hodgkins or Non-Hodgkins) ineligible for Autologous-BMT&#xD;
&#xD;
               -  Myelodysplastic Syndrome&#xD;
&#xD;
          -  Able to provide informed consent or parent/guardian able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consenting 5/6 or 6/6 HLA matched related donor available&#xD;
&#xD;
          -  Single cord blood product with cell count &gt;5 x10E7 Total Nucleated Cells/kg&#xD;
&#xD;
          -  Poor Performance Status: ECOG performance status &gt;= 2 (Karnofsky or Lansky Play&#xD;
             performance&lt;70).&#xD;
&#xD;
          -  Poor Cardiac Function (obtained within 3 weeks of the start of transplant): Left&#xD;
             ventricular ejection fraction &lt;= 45% as determined by MUGA or ECHO. For pediatric&#xD;
             patients LVEF &lt; 45 % or a Shortening Fraction below normal limits for age.&#xD;
&#xD;
          -  Poor Pulmonary Function (obtained within 3 weeks of the start of transplant):&#xD;
&#xD;
               -  FEV1 and FVC &lt;50% of predicted for patients who have not received thoracic or&#xD;
                  mantle irradiation.&#xD;
&#xD;
               -  For patients who have received thoracic or mantle irradiation, FEV1 and FVC &lt;=&#xD;
                  75% of predicted or DLCO &lt;= 50% of predicted&#xD;
&#xD;
               -  For children unable to perform PFTs second to developmental stage, Pulse oximetry&#xD;
                  &lt;= 85% on RA&#xD;
&#xD;
          -  Poor Liver Function (obtained within 1 week of the start of transplant): Bilirubin &gt;=&#xD;
             2.0 mg/dl. (with the exception of patients whose hyperbilirubinemia is the result of&#xD;
             Gilbert's disease)&#xD;
&#xD;
          -  Poor Renal Function (obtained within 3 weeks of the start of transplant): Corrected&#xD;
             CrCl &lt; 60 mg/min. CrCl will be estimated by the Schwartz formula. A measured CrCl or a&#xD;
             GFR may be substituted to determine the subject's CrCl&#xD;
&#xD;
          -  HIV Infection: Patients who are HIV positive. (The role of allogenic transplant in&#xD;
             HIV+ individuals has not been studied)&#xD;
&#xD;
          -  Pregnancy: Patients who are pregnant. (The chemotherapeutic agents used in bone marrow&#xD;
             transplant are teratogenic)&#xD;
&#xD;
          -  Uncontrolled viral, bacterial or fungal infections&#xD;
&#xD;
          -  Patients with symptoms consistent with RSV, influenza A, B or parainfluenza at the&#xD;
             time of enrollment on this study will be assayed for the above viruses and if positive&#xD;
             are not eligible for the trial until are no longer symptomatic (patients may have&#xD;
             continued assay positivity for a period of time post resolution of symptoms second to&#xD;
             the nature of the assay)&#xD;
&#xD;
          -  Presence of concomitant medication or incident condition that would create an&#xD;
             unreasonable risk for the subject to participate in this study as determined by the&#xD;
             investigators (Primary or co-investigators).&#xD;
&#xD;
          -  Patients with known intolerance to or contraindication for any agent that will be used&#xD;
             in the subject's proposed myeloablative or required supportive care regimen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen R. Chen, MD,PhD. MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 2, 2007</study_first_submitted>
  <study_first_submitted_qc>October 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <results_first_submitted>March 13, 2019</results_first_submitted>
  <results_first_submitted_qc>March 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2019</results_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cord blood stem cell transplantation</keyword>
  <keyword>Ex vivo expansion</keyword>
  <keyword>Alternative donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>Patients with a hematologic malignancy who are candidates for myeloablative allogeneic BMT but lack an available matched sibling or unrelated marrow donor are eligible for this study if they have two suitably matched cord blood products with an adequate (1 x 10e7 TNC/kg IBW) but suboptimal (&lt;5 x 10e7 TNC/kg IBW) cell dose. Eligible diagnoses include AML, MDS, ALL after failure of at least one regimen, mixed lineage leukemia, CML beyond first chronic phase, and lymphoma ineligible for autologous transplantation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>Patients with a hematologic malignancy who are candidates for myeloablative allogeneic BMT but lack an available matched sibling or unrelated marrow donor are eligible for this study if they have two suitably matched cord blood products with an adequate (1 x 10e7 TNC/kg IBW) but suboptimal (&lt;5 x 10e7 TNC/kg IBW) cell dose.&#xD;
One cord blood unit is expanded beginning 14 days before graft infusion (6 or 7 days before the start of the preparative regimen). Patients receive a standard myeloablative preparative regimen. The expanded cord blood unit is infused on day 0 and the unmanipulated cord blood unit is expanded on day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" lower_limit="18" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Toxicities Related to Infusion of Expanded Cord Blood Products</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Receive Two Cord Blood Units</title>
            <description>Ex vivo expansion of cord blood: Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicities Related to Infusion of Expanded Cord Blood Products</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Neutrophil Engraftment Within 21 Days</title>
        <description>Number of participants who reached 3 consecutive days with ANC &gt; 500</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Receive Two Cord Blood Units</title>
            <description>Ex vivo expansion of cord blood: Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Engraftment Within 21 Days</title>
          <description>Number of participants who reached 3 consecutive days with ANC &gt; 500</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Engrafted by day 21</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not engrafted by day 21</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality</title>
        <description>Number of participants who died without relapse in less than 100 days.</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Receive Two Cord Blood Units</title>
            <description>Ex vivo expansion of cord blood: Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality</title>
          <description>Number of participants who died without relapse in less than 100 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 100 days</time_frame>
      <desc>Neutrophil count was followed based on regular lab assessments</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>Patients with a hematologic malignancy who are candidates for myeloablative allogeneic BMT but lack an available matched sibling or unrelated marrow donor are eligible for this study if they have two suitably matched cord blood products with an adequate (1 x 10e7 TNC/kg IBW) but suboptimal (&lt;5 x 10e7 TNC/kg IBW) cell dose.&#xD;
One cord blood unit is expanded beginning 14 days before graft infusion (6 or 7 days before the start of the preparative regimen). Patients receive a standard myeloablative preparative regimen. The expanded cord blood unit is infused on day 0 and the unmanipulated cord blood unit is expanded on day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <description>Death due to ARDS, grade 5</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>low neutrophils</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allen Chen, MD,PhD,MHS</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-614-4434</phone>
      <email>chenal@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

